Lungs of infants with RDS and BPD have increased miR-34a expression. a miR-34a expression in cell pellets obtained from tracheal aspirates of neonates in the first PN week, who subsequently did or did not develop BPD. b Next, we used ISH to detect miR-34a in human neonatal lungs. As noted in the representative microphotographs, there was increased violet staining (miR-34a-positive) of the cells in the lungs of RDS and BPD neonates, compared to controls. c Western blot analysis of Tie2 and Ang1 was performed on total homogenates from human lung samples. d, e Densitometric analysis of Tie2 and Ang1 expression from infants born near term with no lung disease compared to near or post term with mild RDS, evolving BPD and established BPD. f A proposed schema for the role of miR-34a in the pathogenesis of BPD. Hyperoxia exposure to the developing lung leads to production and release of the primary (Pri-miR-34a), which is processed into the mature form of miR-34a. Downstream targets of the miR34a signaling pathway include Ang1 and its receptor Tie2, and the anti-apoptotic protein Bcl2; decreased expression of both are known to increase cell death in hyperoxia-induced lung injury models and BPD. In addition, hyperoxia decreases cell proliferation via CDK4 and cyclin D1, both targets of miR34a. The class III histone deacetylator, Sirt1 is also a downstream target of miR-34a, and a decrease in Sirt1 has been associated with enhanced transcription of pro-inflammatory mediators and BPD. The combined effect of enhanced cell death and decreased cell proliferation would be impaired alveolarization in the lung. In addition, miR34a, by suppressing the Ang1/Tie2 signaling pathway and enhancing cell death, results in dysregulated vascularization in the lung. Hence, increased miR-34a results in increased inflammation, impaired alveolarization and dysregulated vascularization in the developing lung—the hallmarks of “new” BPD. RDS: respiratory distress syndrome; BPD: bronchopulmonary dysplasia; Ang1: angiopoietin 1; Sirt1: Sirtuin 1. *P <0.05, **P <0.01, compared with controls, 1-way ANOVA